Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Multiple Myeloma 202Leukemia, Lymphocytic, Chronic, B-Cell 54Recurrence 37Neoplasms, Plasma Cell 30Lymphoma, Mantle-Cell 30Lymphoma 30Lymphoma, Follicular 29Lymphoma, Large B-Cell, Diffuse 27Leukemia 23Leukemia, Myeloid, Acute 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell, Marginal Zone 15Myelodysplastic Syndromes 13Hodgkin Disease 12Waldenstrom Macroglobulinemia 8Prostatic Neoplasms 8Lymphoma, T-Cell 8Smoldering Multiple Myeloma 7Immunoglobulin Light-chain Amyloidosis 7Neoplasms 6Melanoma 6Lymphoma, B-Cell 6Hematologic Diseases 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelomonocytic, Chronic 5Hematologic Neoplasms 5Amyloidosis 5Sezary Syndrome 4

Interventions

ibrutinib 5fludarabine 4Rituximab 4Lenalidomide 3Busulfan 3thymoglobulin 2fludarabine phosphate 2blinatumomab 2Vincristine 2Methotrexate 2Melphalan 2Bendamustine Hydrochloride 2Behavior Therapy 2Alemtuzumab 2tozasertib 1sargramostim 1romiplostim 1pirtobrutinib 1pegaspargase 1palbociclib 1ofatumumab 1obinutuzumab 1mocetinostat 1lirilumab 1forodesine 1fenebrutinib 1enzastaurin 1duvelisib 1Stem Cell Transplantation 1RFT5-SMPT-dgA immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Leukemia, Lymphoid × Lenalidomide × Clear all
NCT01754857 2023-06-27

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

University of Wisconsin, Madison

Phase 2 Completed
36 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01116193 2017-09-14

RV-405 LAL

Institut de Cancérologie de la Loire

Phase 2 Completed
10 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00609869 2015-09-17

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
29 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡